PATENT CLAIM ANALYSIS

Application Number: 16186879
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-02
Patent Classification: ["514", "001400"]

Abstract:
The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.

Claim (Index 34):
A method of modulating ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection, nerve growth, bone metabolism, bone formation and bone development by eliciting an agonist or antagonist effect from a melanocortin receptor according to  claim 14 .

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.46875
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12602010', '14024961', '13074565', '11988468', '15055873']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8818226718980974
- 35 USC 102 Novelty (BERT): 0.6470682846514149
- Combined Prediction Score: 0.8583472331734292
- Mean Citation Score: 625.486862
- Max Citation Score: 672.6033
- Similarity Product: 575.5732745326995

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test